Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Oral Oncol. 2020 May 12;109:104776. doi: 10.1016/j.oraloncology.2020.104776

Table 2.

Characteristics and response outcomes.

Characteristics mPFS 95% CI ORR 95% CI
Total 4.2 months 0.3, 8.1 27.2% 6.0, 61.0
PD-L1
 PD-L1 + 5.7 months 0.3, 11.1 33.3% 8.0, 90.6
 PD-L1 − 2.1 months 0.1, 5.4 25.0% 3.2, 65.1
Line of anti-PD-1 inhibitor
 First-line 5.7 months 0.1, 26.7 40.0% 5.3, 85.3
 Second/beyond line 2.1 months 1.5, 2.7 16.7% 0.4, 64.1
HPV status
 HPV + 1.8 months 0.7, 2.9 0% N/A
 HPV − 5.7 months 0.1, 13.4 37.5% 8.5, 75.5